Adalimumab (ADA) for Uveitis
This trial is testing whether a new drug, adalimumab, is better than existing treatments for a chronic, potentially blinding disease.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are there any unfilled slots in this clinical trial?
"The listed clinical trial on clinicaltrials.gov is searching for participants. The posting dates for this study were September 17th, 2019 and June 16th, 2022 respectively."
What do we know about CON from other previous clinical trials?
"At the moment, 513 clinical studies are underway which focus on Conventional immunosuppression (CON). Out of these CON trials, 112 have progressed to Phase 3. Most investigations into Conventional immunosuppression (CON) originate from Philadelphia, but there are 11,025 research centres spread out across the globe looking into this topic."
Where are the trial sites for this experiment?
"University of California, San Francisco in San Francisco, California, Tennessee Retina in Nashville, Tennessee, and University of Iowa in Iowa City, Iowa are a few example locations where this trial is taking place. In total, there are 21 sites running this study."
What is the mortality rate associated with CON treatment?
"There is some efficacy data and multiple rounds of safety data available for Conventional immunosuppression (CON), so it received a score of 3."
What is the standard treatment that Conventional immunosuppression (CON) is used for?
"Ocular rosacea is most often treated with immunosuppressive drugs, which are also sometimes used to manage transplant patients, those with small cell lung cancer, and people suffering from dermatitis or atopic conditions."
How many people are involved in the research project?
"The clinicaltrials.gov website has the latest information on this study, which is currently looking for 222 participants at 21 sites. The trial was first posted on September 17th, 2019 and was last updated on June 16th, 2020."